Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.29+0.43 (+1.44%)
Close on Nov 13, 2026Market cap $3.38BP/E –Yield –
Amylyx Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Amylyx Pharmaceuticals's cash was $768.13M at Sep 30, 2026. For fiscal 2025 it was $316.98M, up 79.6% from the year before. The highest annual figure on record is $371.36M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $316.98M | +79.6% |
| FY2024 | Dec 31, 2024 | $176.50M | -52.5% |
| FY2023 | Dec 31, 2023 | $371.36M | +7.0% |
| FY2022 | Dec 31, 2022 | $346.95M | +261.0% |
| FY2021 | Dec 31, 2021 | $96.12M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $768.13M | +123.3% |
| Q2 FY2026 | Jun 30, 2026 | $250.76M | +38.7% |
| Q1 FY2026 | Mar 31, 2026 | $279.77M | +37.1% |
| Q4 FY2025 | Dec 31, 2025 | $316.98M | +79.6% |
| Q3 FY2025 | Sep 30, 2025 | $343.99M | +46.8% |
| Q2 FY2025 | Jun 30, 2025 | $180.83M | -41.6% |
| Q1 FY2025 | Mar 31, 2025 | $204.07M | -45.3% |
| Q4 FY2024 | Dec 31, 2024 | $176.50M | -52.5% |
| Q3 FY2024 | Sep 30, 2024 | $234.40M | -34.0% |
| Q2 FY2024 | Jun 30, 2024 | $309.81M | -13.3% |
| Q1 FY2024 | Mar 31, 2024 | $373.29M | +8.0% |
| Q4 FY2023 | Dec 31, 2023 | $371.36M | +7.0% |
| Q3 FY2023 | Sep 30, 2023 | $355.05M | +118.4% |
| Q2 FY2023 | Jun 30, 2023 | $357.28M | +72.9% |
| Q1 FY2023 | Mar 31, 2023 | $345.67M | +35.4% |
| Q4 FY2022 | Dec 31, 2022 | $346.95M | +261.0% |
| Q3 FY2022 | Sep 30, 2022 | $162.59M | – |
| Q2 FY2022 | Jun 30, 2022 | $206.68M | – |
| Q1 FY2022 | Mar 31, 2022 | $255.21M | – |
| Q4 FY2021 | Dec 31, 2021 | $96.12M | – |
See a number that looks wrong?